You can buy or sell VBLT and other stocks, options, ETFs, and crypto commission-free!
Vascular Biogenics Ltd. Ordinary Shares, also called Vascular Biogenics, is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. Read More It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
52 Week High
52 Week Low
Seeking AlphaMar 19
VBL up 11% premarket on encouraging VB-111 data
VBL Therapeutics (NASDAQ:VBLT) is up 11% premarket on modestly higher volume on the heels of new data on anti-cancer gene therapy ofranergene obadenovec (VB-111). The results were presented at the SGO Annual Meeting on Women's Cancer in Honolulu.
Yahoo FinanceMar 14
Earnings Preview: Vascular Biogenics (VBLT) Q4 Earnings Expected to Decline
Vascular Biogenics (VBLT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
-$0.18 per share
Available Mar 28, Pre-Market